Skip to main content

Luteal phase oestradiol administration in ovarian stimulation cycles with GnRH antagonist is comparable to the GnRH agonist (long) protocol

Journal of Assisted Reproduction and Genetics volume 24, pages 326–330 (2007)Cite this article

Abstract

Purpose:

The purpose of the study was to compare the effectiveness of GnRH antagonist with luteal phase estradiol administration to GnRH agonist cycles, long protocol.

Methods:

55 IVF-ICSI patients received oestradiol in the luteal phase of the cycle, before a cycle with GnRH antagonist. Fifty-five patients submitted to IVF-ICSI with the use of agonist were allocated, age matched, as a control group (historical control). The primary outcome was the number of retrieved oocytes.

Results:

Patients were similar in terms of clinical characteristics. No differences were found in the number of oocytes retrieved (study group, 8.1 ± 4.7; control group, 7.4 ± 4.5) or in oocyte quality.

Conclusions:

We clearly demonstrated that the effectiveness of GnRH antagonist when combined with luteal phase estradiol is comparable to GnRH agonist cycles.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

References

  1. Albano C, Smitz J, Camus M, Rietmuller-Winzen H, Van Steirteghem A, Devroey P. Comparison of different doses of gonadotropin-releasing hormone antagonist Cetrorelix during controlled ovarian hyperstimulation. Fertil Steril 1997;67:917–22.

    PubMed  Article  CAS  Google Scholar 

  2. European Orgalutran Study Group, Borm G, Mannaerts B. Treatment with the gonadotropin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. Hum Reprod 2000;15:1490–8.

    PubMed  Article  CAS  Google Scholar 

  3. European Middle East Orgalutran Study Group. Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation. Hum Reprod 2001;16:644–51.

    Article  Google Scholar 

  4. Al-Inany H, Aboulghar M. Gonadotrophin-releasing hormone antagonists for assisted conception. A Cochrane review. Hum Reprod 2002;17:874–85.

    PubMed  Article  CAS  Google Scholar 

  5. Olivennes F, Cunha Filho JS, Fanchin R, Bouchard P, Frydman R. The use of GnRH antagonists in ovarian stimulation. Hum Reprod Update 2002;8:279–90.

    PubMed  Article  CAS  Google Scholar 

  6. Klein NA, Battaglia DE, Fujimoto VY, Davis GS, Bremner WJ, Soules MR. Reproductive aging: accelerated ovarian follicular development associated with a monotropic follicle-stimulating hormone rise in normal older women. J Clin Endocrinol Metab 1996;81:1038–45.

    PubMed  Article  CAS  Google Scholar 

  7. Fanchin R, Cunha-Filho JS, Schonauer LM, Kadoch IJ, Cohen-Bacri P, Frydman R. Coordination of early antral follicles by luteal estradiol administration provides a basis for alternative controlled ovarian hyperstimulation regimens. Fertil Steril 2003;79(2):316–21.

    PubMed  Article  Google Scholar 

  8. Olivennes F, Belaisch-Allart J, Emperaire JC, Dechaud H, Alvarez S, Moreau L, et al. Prospective, randomized, controlled study of in vitro fertilization-embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LHRH) antagonist (cetrorelix) or a depot formula of an LHRH agonist (triptorelin). Fertil Steril 2000;73(2):314–20.

    PubMed  Article  CAS  Google Scholar 

  9. Albano C, Felberbaum RE, Smitz J, Riethmüller-Winzen H, Engel J, Diedrich K, et al. On behalf of the European Cetrorelix Study Group Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. Hum Reprod 2000;15:526–31.

    PubMed  Article  CAS  Google Scholar 

  10. The North American Ganirelix Study Group, Fluker M, Grifo J, Leader A, Levy M, Meldrum D, Muasher SJ, et al. Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation. Fertil Steril 2001;75:38–45.

    PubMed  Article  CAS  Google Scholar 

  11. Fanchin R, Salomon L, Castelo-Branco A, Olivennes F, Frydman N, Frydman R. Luteal estradiol pre-treatment coordinates follicular growth during controlled ovarian hyperstimulation with GnRH antagonists. Hum Reprod 2003;8(12):2698–703.

    Article  CAS  Google Scholar 

  12. Zeleznik AJ. Premature elevation of systemic estradiol reduces serum levels of follicle-stimulating hormone and lengthens the follicular phase of the menstrual cycle in rhesus monkeys. Endocrinology 1981;109:352–5.

    PubMed  CAS  Article  Google Scholar 

  13. De Ziegler D, Jaaskelainen AS, Brioschi PA, Fanchin R, Bulletti C. Synchronization of endogenous and exogenous FSH stimuli in controlled ovarian hyperstimulation (COH). Hum Reprod 1998;13:561–4.

    PubMed  Article  Google Scholar 

  14. Ludwig M, Katalinic A, Banz C, Schröeder AK, Löning M, Weiss JM, et al. Tailoring the GnRH antagonist cetrorelix acetate to individual patients`needs in ovarian stimulation for IVF: results of prospective, randomized study. Hum Reprod 2002;17(11):2842–5.

    PubMed  Article  CAS  Google Scholar 

  15. Cunha-Filho JS, Lemos N, Stein N, Laranjeira A, Passos EP. Vascular endothelial growth factor and inhibin A in follicular fluid of infertile patients who underwent in vitro fertilization with a gonadotropin-releasing hormone antagonist. Fertil Steril 2005;83(4):902–7.

    PubMed  Article  CAS  Google Scholar 

Download references

Acknowledgments

We would like to thank Ana Angélica Gratão and Luciane Baptista for the activities developed in our lab.

Author information

Affiliations

  1. Ob/Gyn depto., Hospital de Clínicas de Porto Alegre, Programa de Pós-graduação em Ciências Médicas, Faculdade de Medicina, Universidade Federal do Rio Grande do Sul, Rua Ramiro Barcellos, 2350, Porto Alegre, RS, CEP 90035-003, Brazil

    J. S. Cunha Filho, L. F. Terres, F. Holanda, F. Freitas, C. Glitz, V. K. Genro & E. Arbo

Authors
  1. J. S. Cunha Filho
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L. F. Terres
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F. Holanda
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. F. Freitas
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C. Glitz
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. V. K. Genro
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. E. Arbo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J. S. Cunha Filho.

Additional information

Capsule

Oestradiol associated to GnRH antagonist may increase the rates of oocytes causing reproductive results to be comparable to the results with the use of agonists.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Cunha Filho, J.S., Terres, L.F., Holanda, F. et al. Luteal phase oestradiol administration in ovarian stimulation cycles with GnRH antagonist is comparable to the GnRH agonist (long) protocol. J Assist Reprod Genet 24, 326–330 (2007). https://doi.org/10.1007/s10815-007-9125-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10815-007-9125-x

Keywords

  • GnRH antagonists
  • GnRH agonist
  • Follicular cohort
  • Homogenization
  • Luteal phase oestradiol